- Patients with diffuse large B-cell lymphoma (DLBCL) and abdominal lymph node involvement had inferior lymphoma-specific survival (LSS) and more characteristics associated with aggressive disease vs those without abdominal nodal involvement.
Why this matters
- Outcomes with various sites of extranodal DLBCL have been well studied, but less is known regarding sites of nodal involvement.
- Study to investigate the prognostic implications of abdominal lymph node involvement in 249 patients with de novo DLBCL.
- All patients had been treated with R-CHOP (rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone) or similar regimens.
- Patient age range, 26-86 years.
- Funding: None disclosed.
- 63% of patients with DLBCL had abdominal nodal disease.
- Compared with patients without abdominal lymph node involvement, those with abdominal nodal disease had:
- Inferior LSS: HR, 1.79 (95% CI, 1.01-3.17; P=.04).
- Higher age-adjusted international prognostic index (IPI) scores: 65% with IPI 2-3 vs 27% (P<.001>
- High lactate dehydrogenase: 69% vs 44% (P<.001>
- Greater frequency of advanced-stage disease: 72% with stage III-IV disease vs 31% (P<.001>
- Greater frequency of bulky disease: 33% vs 10% (P<.001>
- Greater frequency of B symptoms: 50% vs 26% (P<.001>
- Retrospective data.